|
|
发表于 2008-11-22 04:17:19
|
显示全部楼层
来自： 美国
原帖由 amei 于 2008-11-20 15:18 发表 
jimmy,可以帮忙搜索一些资料么？低分子肝素联合抑制血管生成的靶向药物是增强疗效还是减弱疗效呢？
找到几个间接提到TARCEVA和低分子肝素联合用，但都没有直接讨论效果。
1)[url=http://74.125.95.132/search?q=cache:yzMfvvItZWAJ nctalk.com/bbPress/topic.php%3Fid%3D117+low-molecular-weight+heparin+tarceva&hl=en&ct=clnk&cd=1&gl=us]http://74.125.95.132/search?q=cache:yzMfvvItZWAJnctalk.com/bbPress/topic.php%3Fid%3D117+low-molecular-weight+heparin+tarceva&hl=en&ct=clnk&cd=1&gl=us[/url]
这介绍了TARCEVA和低分子肝素联合用可能剂量有变化
Wendy,
There's some suggestive evidence that low molecular weightheparins (injected under the skin, not orally administered) mayactually be associated with better survival in patients with cancer,compared with coumadin. It's not conclusive at this point, and to behonest it's been a while since I reviewed it, so I would just say thatthe data are intriguing but haven't changed routine practice at thispoint, which is much more likely to include coumadin. I don't believethere's any reason to expect that the tarceva issue is directly related to this issue, except that tarcevatends to lead to lower levels of coumadin being needed to keep the INRat a certain target (so the dose often changes when given with tarceva), not that there's an particular favorable interaction of tarceva with lovenox.
I will need to dig up what I can on the low molecular weight heparin and cancer survival issue and write a proper post about it.
-Dr. West
2) http://www.compassionateoncology.org/pdfs/AntiangiogenicCocktail082508.pdf
这篇文章介绍了他们的鸡尾酒配方(包括低分子肝素,索拉非尼，以前用过 IRESSA，TARCEVA，AVASTIN 等等)，看来是可以联用的
As of August 2008, I believe (opinion) that 95% of the
beneficial results from AAC are due to Leukine and
thalidomide/Revlimid. Some of the minor AAC players that may
help our patients include Proscar, Avodart, Celebrex (but only
200 mg once a day to reduce the risk of cardiovascular
complications), and statins (like Crestor) to lower cholesterol
and reduce the risk of dying from cardiovascular events. A
number of studies have found that men on statins who develop
prostate cancer have a lower risk of developing advanced or
metastatic cancer, as well as a lower risk of dying from
metastatic prostate cancer. Still other minor AAC players
include anticoagulation with low-molecular weight heparin (not
warfarin/Coumadin),
mini-mini-dose alpha interferon, and
perhaps vitamin D.
Avastin is also possibly a major
significant player and we try to use it in certain settings,
but I do not believe it is anywhere near as effective as
Leukine and thalidomide/Revlimid. We also may use a metronomic
schedule of oral cyclophosphamide (Cytoxan) in tiny mini-doses.
At times, we may add another category of drugs called targeted
therapy. Currently, our targeted drug of choice is Nexavar,
but previously we tried Iressa, Tarceva, Sutent, and Gleevec.
[ 本帖最后由 jimmy112199 于 2008-11-22 05:53 编辑 ] |
|
IP卡
狗仔卡
显身卡
发表于 2008-11-20 14:46:28
